Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.6K

The Relationship between Metabolic Parameters, Cardiac Parameters and MIC-1/GDF15 in Obese Children

S A Yuca1, E A Cimbek1, Y Şen1

  • 1Department of Pediatric Endocrinology, Selçuk University Medical School, Selçuklu, Turkey.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|October 18, 2016
PubMed

Insights

Growth differentiation factor-15 (MIC-1/GDF15) levels did not differ between normal-weight and obese children. However, MIC-1/GDF15 correlated with inflammation and aortic dimensions, suggesting a potential link to future cardiovascular issues.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Health
  • Metabolic Syndrome Research

Background:

  • Childhood obesity predicts adult obesity and is linked to type 2 diabetes, metabolic syndrome, dyslipidemia, coronary artery disease, and subclinical inflammation.
  • Growth differentiation factor-15 (MIC-1/GDF15), a cytokine elevated during inflammation, is found in increased serum concentrations in adults with obesity and is associated with cardiometabolic risk.
  • Identifying obese children at higher risk for cardiometabolic complications is crucial, yet the relationship between MIC-1/GDF15 and obesity parameters in children remains unstudied.

Purpose of the Study:

  • To investigate the relationship between serum MIC-1/GDF15 concentrations and various parameters in obese children.
  • To explore the potential role of MIC-1/GDF15 as a biomarker linking childhood obesity to long-term cardiometabolic risk.

Main Methods:

  • Serum MIC-1/GDF15 concentrations were measured in obese children using ELISA.
  • The study evaluated the correlation of MIC-1/GDF15 with anthropometric, biochemical (including CRP and ALT), and echocardiographic parameters.

Main Results:

  • No significant difference in serum MIC-1/GDF15 levels was observed between normal-weight and obese children.
  • When both groups were analyzed together, MIC-1/GDF15 showed a positive correlation with C-reactive protein (CRP), alanine aminotransferase (ALT), and aortic dimension.
  • These findings suggest a potential association between MIC-1/GDF15 and inflammatory and cardiovascular markers in children.

Conclusions:

  • MIC-1/GDF15 may represent a link between childhood obesity and the development of future cardiometabolic complications.
  • Further research is warranted to determine if MIC-1/GDF15 plays a role in the early inflammatory, cardiac, and metabolic changes associated with childhood obesity.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.8K
Assessment of Child Anthropometry in a Large Epidemiologic Study09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

28.0K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K